fenretinide
Trials 42
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2025-08-14 | Island Pharmaceuticals | Results Presentation to the Third Annual Dengue Endgame Summit irmau.com ↗
The attached presentation provides further data from the Company’s recently completed Phase 2a/b PROTECT trial using ISLA-101 (refer ASX announcement: 12 June 2025), supporting the ongoing development of the molecule as a dengue countermeasure. |
| 2024-06-03 | Island Pharmaceuticals | Results Investor Presentation irmau.com ↗
ISLA-101 was safe and well tolerated |
| 2024-04-22 | Island Pharmaceuticals | Results Investor Presentation - Asia Bio Partnering irmau.com ↗
ISLA-101 was shown to be safe and well tolerated |
| 2023-05-16 | Island Pharmaceuticals | Regulatory Island receives FDA go-ahead for ISLA-101 program irmau.com ↗
Lifting of the Clinical Hold will allow the Company to proceed with the Single Ascending Dose study requested by the FDA. |
| 2022-03-15 | SciTech Development, Inc. | Regulatory SciTech Announces Launch of Equity Crowdfunding Campaign on StartEngine scitechdevelopment.com ↗
We are also pleased to announce that ST-001 has an FDA approved Investigational New Drug Application (IND) and Orphan Drug Designation (ODD) for two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T -cell lymphoma (CTCL). |
| 2019-12-23 | SciTech Development, Inc. | Regulatory FDA Accepts SciTech's IND Application for ST-001 nanoFenretinide in Patients with T-Cell Lymphoma scitechdevelopment.com ↗
The U.S. Food and Drug Administration (FDA) has accepted SciTech Development's Investigational New Drug (IND) Application for ST-001 nanoFenretinide, an experimental treatment for T-cell non-Hodgkin's lymphoma (NHL). |
| 2018-02-01 | SciTech Development, Inc. | Regulatory SciTech’s Oncology Drug Granted Orphan Status scitechdevelopment.com ↗
SciTech Development is pleased to announce that the U.S. Food & Drug Administration (FDA) has recently granted its lead drug product ST-001 Orphan Drug Status for the treatment of T-cell lymphoma. |
All press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-14 | Island Pharmaceuticals | Presentation to the Third Annual Dengue Endgame Summit irmau.com ↗ |
| 2024-06-03 | Island Pharmaceuticals | Investor Presentation irmau.com ↗ |
| 2024-04-22 | Island Pharmaceuticals | Investor Presentation - Asia Bio Partnering irmau.com ↗ |
| 2023-05-16 | Island Pharmaceuticals | Island receives FDA go-ahead for ISLA-101 program irmau.com ↗ |
| 2022-03-15 | SciTech Development, Inc. | SciTech Announces Launch of Equity Crowdfunding Campaign on StartEngine scitechdevelopment.com ↗ |
| 2019-12-23 | SciTech Development, Inc. | FDA Accepts SciTech's IND Application for ST-001 nanoFenretinide in Patients with T-Cell Lymphoma scitechdevelopment.com ↗ |
| 2018-02-01 | SciTech Development, Inc. | SciTech’s Oncology Drug Granted Orphan Status scitechdevelopment.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 49 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fenretinide | “Fenretinide is an anticancer agent that may work differently than standard chemotherapy medicines.” NCT02075177 ↗ |
| Known as | 4-HPR | “Induction of apoptosis is a unique feature of fenretinide (4-hydroxyphenylretinamide, 4-HPR),(2) the most widely studied retinoid in clinical trials of breast cancer...” NCT01479192 ↗10“A Multicenter Randomized Double-Blinded Trial for Chemoprevention of Ovarian Cancer: Modulation of Biomarkers and Spectral Properties Using Contrast Enhanced Ultrasound in...” NCT00098800 ↗ “The synthetic retinoid fenretinide (N-(4-hydroxyphenyl)retinamide, 4-HPR) has shown promising anticancer activity in preclinical studies, but its limited oral bioavailability...” PMID 21498721 ↗ Mar 2011 “A Randomized, Double Blind, Placebo-Controlled Phase II Clinical Trial of N(4-Hydroxy-phenyl)Retinamide (Fenretinide, 4HPR) in Oral Leukoplakia” NCT00004161 ↗ “Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder in Patients With Recurrent or Resistant Neuroblastoma” NCT00295919 ↗ “To evaluate the efficacy of fenretinide (4-HPR) in patients with recurrent ovarian cancer or primary peritoneal carcinoma.” NCT00026091 ↗ “Fenretinide (4-HPR) is a synthetic retinoid that induces cytotoxicity through dihydroceramide production.” PMID 37199745 ↗ May 2023 “4-HPR (Fenretinide) is given as a continuous intravenous infusion (CIV) for five consecutive days.” NCT00387504 ↗ “A Phase II Trial of Fenretinide (4-HPR) in Biochemically Recurrent, Hormone Naive Prostate Cancer” NCT00080899 ↗ “Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies” NCT00104923 ↗ “Fenretinide (4-HPR)” NCT00102635 ↗ |
| Known as | 4-hydroxyphenylretinamide | “Induction of apoptosis is a unique feature of fenretinide (4-hydroxyphenylretinamide, 4-HPR),(2) the most widely studied retinoid in clinical trials of breast cancer...” NCT01479192 ↗ |
| Known as | Dihydroceramide N-(4-Hydroxyphenyl retinamide) | “fenretinide (Dihydroceramide N-(4-Hydroxyphenyl retinamide) on severity” NCT00534898 ↗ |
| Known as | FMS | “The goal of this clinical trial is to determine the effect of a mucoadhesive system that releases the vitamin A derivative, fenretinide (FMS), on precancerous surface...” NCT07149220 ↗ |
| Known as | HPR | “Determine the maximum tolerated dose of fenretinide (HPR) in children with high risk solid tumors.” NCT00003191 ↗ |
| Known as | IND-40, 294 | “Phase II Trial Of Fenretinide (NSC-374551; IND-40, 294) In Patients With Relapsed Small Cell Lung Cancer” NCT00009971 ↗ |
| Known as | LXS | “The purpose of this study is to determine the effectiveness of fenretinide (4-HPR/LXS) plus ketoconazole in the treatment of recurrent ovarian cancer or primary peritoneal carcinoma.” NCT01535157 ↗ |
| Known as | N-(4-hydroxyphenyl)retinamide | “The synthetic retinoid fenretinide (N-(4-hydroxyphenyl)retinamide, 4-HPR) has shown promising anticancer activity in preclinical studies, but its limited oral bioavailability...” PMID 21498721 ↗ Mar 20111“A Randomized, Double Blind, Placebo-Controlled Phase II Clinical Trial of N(4-Hydroxy-phenyl)Retinamide (Fenretinide, 4HPR) in Oral Leukoplakia” NCT00004161 ↗ |
| Known as | NSC 374551 | “Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.” PMID 15514370 ↗ Nov 20044“Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder Plus Ketoconazole in Patients With Recurrent or Resistant Neuroblastoma” NCT02075177 ↗ “Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder in Patients With Recurrent or Resistant Neuroblastoma” NCT00295919 ↗ “Phase II Trial Of Fenretinide (NSC-374551; IND-40, 294) In Patients With Relapsed Small Cell Lung Cancer” NCT00009971 ↗ “A Phase I Study of Fenretinide (NSC #374551) in Children With High Risk Solid Tumors” NCT00003191 ↗ |
| Modality | Small molecule | “Fenretinide, a synthetic form of retinoid” PMID 15744595 ↗ Mar 2005 |
| Route | Oral | “Patients also receive either oral fenretinide or oral placebo daily for 5 years, beginning within 2 weeks after completion of any radiotherapy, or within 2 weeks of...” NCT00002646 ↗ |